TABLE V.
Second-line treatment in 46 patients receiving first-line platinum
| Treatment | Value [n (%)] |
|---|---|
| Monotherapy | |
|
| |
| Cetuximab | 20 (43) |
|
| |
| Cetuximab + RT | 1 (2) |
|
| |
| Docetaxel | 6 (13) |
|
| |
| Docetaxel + RT | 0 |
|
| |
| 5FU ± RT | 1 (2) |
|
| |
| Gemcitabine ± RT | 0 |
|
| |
| Methotrexate | 4 (9) |
|
| |
| Methotrexate + RT | 0 |
|
| |
| Paclitaxel | 4 (9) |
|
| |
| Paclitaxel + RT | 2 (4) |
|
| |
| Other ± RT | 2 (4) |
|
| |
| Platinum | 2 (4) |
|
| |
| Platinum + RT | 0 |
|
| |
| Combination therapy | |
|
| |
| EXTREME regimena ± RT | 1 (2) |
|
| |
| Platinum–5FU ± RT | 0 |
|
| |
| Platinum–taxane ± RT | 1 (2) |
|
| |
| Other ± RT | 2 (4) |
a
Platinum–5FU–cetuximab.
5FU = fluorouracil; RT = radiotherapy.